MeiraGTx Holdings plc Foreign Currency Transaction Gain (Loss), before Tax
MeiraGTx Holdings plc (MGTX) reported Foreign Currency Transaction Gain (Loss), before Tax of -$1.47 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2026-08-13
- MeiraGTx Holdings plc foreign currency transaction gain (loss), before tax for the quarter ending 2026-06-30 was -$1.47M, a 117.00% decline year-over-year.
- MeiraGTx Holdings plc foreign currency transaction gain (loss), before tax for the quarter ending 2026-03-31 was -$2.84M, a 176.95% decline year-over-year.
- MeiraGTx Holdings plc foreign currency transaction gain (loss), before tax for the quarter ending 2025-12-31 was -$8.61M.
- MeiraGTx Holdings plc foreign currency transaction gain (loss), before tax for the quarter ending 2025-09-30 was -$1.56M, a 144.99% decline year-over-year.
- MeiraGTx Holdings plc foreign currency transaction gain (loss), before tax for fiscal 2025 was $2.15M.
- MeiraGTx Holdings plc foreign currency transaction gain (loss), before tax for fiscal 2024 was -$2.89M, a 131.03% decline from fiscal 2023.
- MeiraGTx Holdings plc foreign currency transaction gain (loss), before tax for fiscal 2023 was $9.30M.
- MeiraGTx Holdings plc foreign currency transaction gain (loss), before tax for fiscal 2022 was -$9.45M.
| Period end | Foreign Currency Transaction Gain (Loss), before Tax 3 month | Foreign Currency Transaction Gain (Loss), before Tax 3 month as first filed | Foreign Currency Transaction Gain (Loss), before Tax 6 month | Foreign Currency Transaction Gain (Loss), before Tax 6 month as first filed | Foreign Currency Transaction Gain (Loss), before Tax 9 month | Foreign Currency Transaction Gain (Loss), before Tax 9 month as first filed | Foreign Currency Transaction Gain (Loss), before Tax 12 month | Foreign Currency Transaction Gain (Loss), before Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$1.47M 10-Q · filed 2026-08-13 | -$4.30M 10-Q · filed 2026-08-13 | -$12.91M derived: sum of 3 quarters · filed 2026-08-13 | -$14.47M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | -$2.84M 10-Q · filed 2026-05-14 | -$11.44M derived: sum of 2 quarters · filed 2026-05-14 | -$13.00M derived: sum of 3 quarters · filed 2026-05-14 | -$4.38M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | -$8.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$10.16M derived: sum of 2 quarters · filed 2026-03-30 | -$1.54M derived: sum of 3 quarters · filed 2026-08-13 | $2.15M 10-K · filed 2026-03-30 | ||||
| 2025-09-30 | -$1.56M 10-Q · filed 2025-11-13 | $7.07M derived: sum of 2 quarters · filed 2026-08-13 | $10.75M 10-Q · filed 2025-11-13 | $5.22M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $8.62M 10-Q · filed 2026-08-13 | $12.31M 10-Q · filed 2026-08-13 | $6.78M derived: sum of 3 quarters · filed 2026-08-13 | $10.24M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $3.69M 10-Q · filed 2026-05-14 | -$1.84M derived: sum of 2 quarters · filed 2026-05-14 | $1.62M derived: sum of 3 quarters · filed 2026-05-14 | $1.34M derived: sum of 4 quarters · filed 2026-05-14 | ||||
| 2024-12-31 | -$5.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$2.07M derived: sum of 2 quarters · filed 2026-03-30 | -$2.35M derived: sum of 3 quarters · filed 2026-03-30 | -$2.89M 10-K · filed 2026-03-30 | ||||
| 2024-09-30 | $3.46M 10-Q · filed 2025-11-13 | $3.18M derived: sum of 2 quarters · filed 2025-11-13 | $2.64M 10-Q · filed 2025-11-13 | $14.86M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | -$284.00K 10-Q · filed 2025-08-14 | -$819.00K 10-Q · filed 2025-08-14 | $11.40M derived: sum of 3 quarters · filed 2025-08-14 | $2.72M derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2024-03-31 | -$535.00K 10-Q · filed 2025-05-13 | $11.68M derived: sum of 2 quarters · filed 2025-05-13 | $3.00M derived: sum of 3 quarters · filed 2025-05-13 | $4.91M derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | $12.21M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $3.54M derived: sum of 2 quarters · filed 2025-03-13 | $5.44M derived: sum of 3 quarters · filed 2025-03-13 | $9.30M 10-K · filed 2025-03-13 | ||||
| 2023-09-30 | -$8.68M 10-Q · filed 2024-11-13 | -$6.77M derived: sum of 2 quarters · filed 2024-11-13 | -$2.92M 10-Q · filed 2024-11-13 | $13.54M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | $1.91M 10-Q · filed 2024-08-12 | $5.76M 10-Q · filed 2024-08-12 | $22.22M derived: sum of 3 quarters · filed 2024-08-12 | $9.38M derived: sum of 4 quarters · filed 2024-08-12 | ||||
| 2023-03-31 | $3.86M 10-Q · filed 2024-05-09 | $20.32M derived: sum of 2 quarters · filed 2024-05-09 | $7.48M derived: sum of 3 quarters · filed 2024-05-09 | -$2.95M derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | $16.46M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $3.62M derived: sum of 2 quarters · filed 2024-03-15 | -$6.80M derived: sum of 3 quarters · filed 2024-03-15 | -$9.45M 10-K · filed 2024-03-15 | ||||
| 2022-09-30 | -$12.84M 10-Q · filed 2023-11-14 | -$23.26M derived: sum of 2 quarters · filed 2023-11-14 | -$25.91M 10-Q · filed 2023-11-14 | -$27.60M derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | -$10.43M 10-Q · filed 2023-08-10 | -$13.07M 10-Q · filed 2023-08-10 | -$14.77M derived: sum of 3 quarters · filed 2023-08-10 | -$18.13M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | -$2.65M 10-Q · filed 2023-05-11 | -$4.34M derived: sum of 2 quarters · filed 2023-05-11 | -$7.71M derived: sum of 3 quarters · filed 2023-05-11 | -$7.33M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | -$1.69M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | -$5.06M derived: sum of 2 quarters · filed 2023-03-14 | -$4.68M derived: sum of 3 quarters · filed 2023-03-14 | -$6.29M 10-K · filed 2023-03-14 | ||||
| 2021-09-30 | -$3.37M 10-Q · filed 2022-11-10 | -$3.37M 10-Q · filed 2021-11-10 | -$2.99M derived: sum of 2 quarters · filed 2022-11-10 | -$4.60M 10-Q · filed 2022-11-10 | -$1.94M derived: sum of 4 quarters · filed 2022-11-10 | |||
| 2021-06-30 | $381.00K 10-Q · filed 2022-08-11 | -$1.23M 10-Q · filed 2022-08-11 | $1.43M derived: sum of 3 quarters · filed 2022-08-11 | $3.30M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | -$1.61M 10-Q · filed 2022-05-12 | $1.04M derived: sum of 2 quarters · filed 2022-05-12 | $2.92M derived: sum of 3 quarters · filed 2022-05-12 | $2.57M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $2.66M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $4.53M derived: sum of 2 quarters · filed 2022-03-10 | $4.18M derived: sum of 3 quarters · filed 2022-03-10 | $3.43M 10-K · filed 2022-03-10 | $3.43M 10-K · filed 2021-03-11 | |||
| 2020-09-30 | $1.88M 10-Q · filed 2021-11-10 | $1.88M 10-Q · filed 2020-11-05 | $1.52M derived: sum of 2 quarters · filed 2021-11-10 | $767.00K 10-Q · filed 2021-11-10 | $766.86K 10-Q · filed 2020-11-05 | $848.73K derived: sum of 4 quarters · filed 2021-11-10 | ||
| 2020-06-30 | -$352.00K 10-Q · filed 2021-08-11 | -$351.86K 10-Q · filed 2020-08-06 | -$1.11M 10-Q · filed 2021-08-11 | -$1.11M 10-Q · filed 2020-08-06 | -$1.03M derived: sum of 3 quarters · filed 2021-08-11 | -$910.80K derived: sum of 4 quarters · filed 2021-08-11 | ||
| 2020-03-31 | -$757.00K 10-Q · filed 2021-05-11 | -$756.70K 10-Q · filed 2020-05-07 | -$674.27K derived: sum of 2 quarters · filed 2021-05-11 | -$558.80K derived: sum of 3 quarters · filed 2021-05-11 | -$275.63K derived: sum of 4 quarters · filed 2021-05-11 | |||
| 2019-12-31 | $82.73K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $198.20K derived: sum of 2 quarters · filed 2021-03-11 | $481.37K derived: sum of 3 quarters · filed 2021-03-11 | $3.20M 10-K · filed 2021-03-11 | ||||
| 2019-09-30 | $115.47K 10-Q · filed 2020-11-05 | $398.64K derived: sum of 2 quarters · filed 2020-11-05 | $3.12M 10-Q · filed 2020-11-05 | $1.72M derived: sum of 4 quarters · filed 2020-11-05 | ||||
| 2019-06-30 | $283.18K 10-Q · filed 2020-08-06 | $3.00M 10-Q · filed 2020-08-06 | $1.60M derived: sum of 3 quarters · filed 2020-08-06 | $925.19K derived: sum of 4 quarters · filed 2020-08-06 | ||||
| 2019-03-31 | $2.72M 10-Q · filed 2020-05-07 | $1.32M derived: sum of 2 quarters · filed 2020-05-07 | $642.02K derived: sum of 3 quarters · filed 2020-05-07 | -$2.08M derived: sum of 4 quarters · filed 2020-05-07 | ||||
| 2018-12-31 | -$1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | -$2.08M derived: sum of 2 quarters · filed 2020-03-11 | -$4.80M derived: sum of 3 quarters · filed 2020-03-11 | -$3.82M 10-K · filed 2020-03-11 | ||||
| 2018-09-30 | -$677.49K 10-Q · filed 2019-11-07 | -$3.40M derived: sum of 2 quarters · filed 2019-11-07 | -$2.43M 10-Q · filed 2019-11-07 | -$1.74M derived: sum of 4 quarters · filed 2019-11-07 | ||||
| 2018-06-30 | -$2.73M 10-Q · filed 2019-08-07 | -$1.75M 10-Q · filed 2019-08-07 | -$1.06M derived: sum of 3 quarters · filed 2019-08-07 | -$670.76K derived: sum of 4 quarters · filed 2019-08-07 | ||||
| 2018-03-31 | $978.62K 10-Q · filed 2019-05-14 | $1.66M derived: sum of 2 quarters · filed 2019-05-14 | $2.06M derived: sum of 3 quarters · filed 2019-05-14 | $2.51M derived: sum of 4 quarters · filed 2019-05-14 | ||||
| 2017-12-31 | $685.72K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | $1.08M derived: sum of 2 quarters · filed 2019-03-26 | $1.53M derived: sum of 3 quarters · filed 2019-03-26 | $1.68M 10-K · filed 2019-03-26 | ||||
| 2017-09-30 | $391.52K 10-Q · filed 2018-11-08 | $841.15K derived: sum of 2 quarters · filed 2018-11-08 | $990.39K 10-Q · filed 2018-11-08 | |||||
| 2017-06-30 | $449.63K 10-Q · filed 2018-08-08 | $598.87K 10-Q · filed 2018-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |